

```
=> file registry
FILE 'REGISTRY' ENTERED AT 15:21:37 ON 17 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)
```

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 MAY 2007 HIGHEST RN 934961-09-8
DICTIONARY FILE UPDATES: 16 MAY 2007 HIGHEST RN 934961-09-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.


REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

```
=> d ide L10

L10  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2007 ACS on STN
RN  11070-68-1  REGISTRY
ED  Entered STN: 16 Nov 1984
CN  L-Glutamic acid, ion(1-) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN  Glutamic acid, ion(1-), L- (8CI)
OTHER NAMES:
CN  Glutamate
CN  Glutamate(1-)
CN  Glutamic acid ion(1-)
CN  L-Glutamate ion
FS  STEREOSEARCH
DR  12305-04-3, 125719-06-4, 65014-53-1, 129309-24-6, 102187-90-6, 95533-49-6
MF  C5 H8 N O4
CI  COM
LC  STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS,
     CASREACT, CIN, CSNB, EMBASE, GMELIN*, PIRA, PROMT, TOXCENTER, TULSA,
     USPAT2, USPATFULL
     (*File contains numerically searchable property data)
```

Absolute stereochemistry.




222 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

222 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d ide L11

L11 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN
RN 328-50-7 REGISTRY
ED Entered STN: 16 Nov 1984
CN Pentanedioic acid, 2-oxo- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Glutaric acid, 2-oxo- (8CI)
OTHER NAMES:
CN *α*-keto-Glutamic acid
CN *α*-Ketoglutaric acid
CN *α*-Oxoglutaric acid
CN *α*-Oxopentanedioic acid
CN 2-Ketoglutaric acid
CN 2-Oxo-1,5-pentanedioic acid
CN 2-Oxoglutaric acid
CN 2-Oxopentanedioic acid
CN NSC 17391
DR 27175-99-1
MF C5 H6 O5
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CABA,
CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM, CSNB,
DDFU, DETHERM*, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE,
MRCK*, MSDS-OHS, NAPRALERT, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USPAT2,
USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8731 REFERENCES IN FILE CA (1907 TO DATE)
151 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
8742 REFERENCES IN FILE CAPLUS (1907 TO DATE)
15 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> => file registry

FILE 'REGISTRY' ENTERED AT 17:05:02 ON 17 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 16 MAY 2007 HIGHEST RN 934961-09-8
DICTIONARY FILE UPDATES: 16 MAY 2007 HIGHEST RN 934961-09-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>


=> d ide L87 1-18

L87 ANSWER 1 OF 18 REGISTRY COPYRIGHT 2007 ACS on STN
RN 118488-53-2 REGISTRY
ED Entered STN: 20 Jan 1989
CN Acetic acid, fluoro-, radical ion(1+) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Fluoroacetic acid radical cation
MF C2 H3 F O2
CI RIS
SR CA
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L87 ANSWER 2 OF 18 REGISTRY COPYRIGHT 2007 ACS on STN
RN 52316-02-6 REGISTRY
ED Entered STN: 16 Nov 1984
CN Ethoxy, 2-fluoro-1-oxo- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Fluoroacetate free radical
MF C2 H2 F O2
LC STN Files: CA, CAPLUS



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L87 ANSWER 3 OF 18 REGISTRY COPYRIGHT 2007 ACS on STN
RN 35597-44-5 REGISTRY
ED Entered STN: 16 Nov 1984
CN Butanoic acid, 2-amino-4-(hydroxymethylphosphinyl)-, (2S)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Butanoic acid, 2-amino-4-(hydroxymethylphosphinyl)-, (S)-
OTHER NAMES:
CN (S)-Phosphinothricin
CN Basta
CN L-2-Amino-4-(hydroxymethylphosphinyl)butanoic acid
CN L-Glufosinate
CN L-Phosphinothricin
CN Phosphinothricin
CN Phosphinothricine
CN s-Glufosinate
FS STEREOSEARCH
DR 121783-99-1, 125604-94-6
MF C5 H12 N O4 P
CI COM
LC STN Files: AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMINFORMRX, CHEMLIST, CIN, DDFU, DRUGU, EMBASE, GMELIN*, MRCK*, NAPRALERT, PROMT, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

884 REFERENCES IN FILE CA (1907 TO DATE)
24 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
884 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L87 ANSWER 4 OF 18 REGISTRY COPYRIGHT 2007 ACS on STN
RN 34364-34-6 REGISTRY
ED Entered STN: 16 Nov 1984
CN Furancarboxylic acid, bromo- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Furoic acid, bromo- (8CI)
OTHER NAMES:
CN Bromofuroate
MF C5 H3 Br O3
CI IDS
LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, USPATFULL




D1-Br

D1-CO₂H

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L87 ANSWER 5 OF 18 REGISTRY COPYRIGHT 2007 ACS on STN
RN 27774-13-6 REGISTRY
ED Entered STN: 16 Nov 1984
CN Vanadium, oxo[sulfato(2-)-κO]- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Vanadium, oxosulfato- (8CI)
CN Vanadium, oxo[sulfato(2-)-O]-
CN Vanadyl sulfate (VO(SO₄)) (6CI)
OTHER NAMES:
CN C.I. 77940
CN Oxo(sulfato)vanadium
CN Oxovanadium(IV) sulfate
CN Vanadium oxide sulfate (VO(SO₄))
CN Vanadium oxosulfate
CN Vanadium oxysulfate (VOSO₄)
CN Vanadium sulfate (VO(SO₄))
CN Vanadyl monosulfate
CN Vanadyl sulfate
DR 12036-78-1, 13767-17-4, 13864-22-7, 1344-64-5, 102500-64-1, 102500-65-2,
102500-66-3, 102500-67-4, 102500-68-5, 102500-69-6, 102500-70-9,
102500-71-0, 102512-68-5, 102512-69-6, 102512-70-9, 102512-71-0,
102512-72-1, 3547-25-9, 410546-95-1
MF 05 S V
CI CCS, COM
LC STN Files: ADISNEWS, AGRICOLA, AQUIRE, BIOSIS, BIOTECHNO, CA, CAOLD,
CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHEM, CSNB, DDFU, DETHERM*,
DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*,
MSDS-OHS, RTECS*, TOXCENTER, ULIDAT, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1773 REFERENCES IN FILE CA (1907 TO DATE)
26 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1782 REFERENCES IN FILE CAPLUS (1907 TO DATE)

19 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L87 ANSWER 6 OF 18 REGISTRY COPYRIGHT 2007 ACS on STN
RN 21752-32-9 REGISTRY
ED Entered STN: 16 Nov 1984
CN Butanoic acid, 2-amino-4-[[S(S)]-S-methylsulfonimidoyl]-, (2S)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Butanoic acid, 2-amino-4-(S-methylsulfonimidoyl)-, [S-(R*,R*)]-
CN Sulfoximine, S-(3-amino-3-carboxypropyl)-S-methyl-, (S)-L- (8CI)
OTHER NAMES:
CN L-Methionine-(S)-sulfoximine
FS STEREOSEARCH
DR 54631-79-7, 110202-65-8
MF C5 H12 N2 O3 S
CI COM
LC STN Files: AGRICOLA, BEILSTEIN*, BIOSIS, CA, CAPLUS, TOXCENTER, USPAT2,
USPATFULL
(*File contains numerically searchable property data)


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

42 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
42 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L87 ANSWER 7 OF 18 REGISTRY COPYRIGHT 2007 ACS on STN
RN 14333-18-7 REGISTRY
ED Entered STN: 16 Nov 1984
CN Vanadate (VO43-), (T-4)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Vanadate (VO43-) (8CI)
OTHER NAMES:
CN Orthovanadate
CN Tetraoxovanadate(3-)
CN Vanadate (VO43-) ion
CN Vanadate ion (VO43-)
DR 76008-43-0
MF O4 V
CI CCS, COM
LC STN Files: AGRICOLA, AQUIRE, BIOSIS, BIOTECHNO, CA, CABA, CAPLUS, DDFU,
DRUGU, EMBASE, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



1414 REFERENCES IN FILE CA (1907 TO DATE)
 75 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1415 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L87 ANSWER 8 OF 18 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 12427-35-9 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN 1,2,3-Propanetricarboxylic acid, 1-fluoro-2-hydroxy-, ion(1-) (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Citric acid, fluoro-, ion(1-) (8CI)
 OTHER NAMES:
 CN **Fluorocitrate ion**
 MF C6 H6 F O7



L87 ANSWER 9 OF 18 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 7532-39-0 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN Coenzyme A, S-(benzeneacetate) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Acetic acid, phenylthio-, S-ester with coenzyme A (8CI)
 CN Coenzyme A, S-(phenylacetate) (6CI, 8CI)
 OTHER NAMES:
 CN Phenylacetyl CoA
 CN Phenylacetyl coenzyme A
 FS STEREOSEARCH
 MF C29 H42 N7 O17 P3 S
 CI COM
 LC STN Files: AGRICOLA, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, EMBASE,
 MEDLINE, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

58 REFERENCES IN FILE CA (1907 TO DATE)
 3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 59 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L87 ANSWER 10 OF 18 REGISTRY COPYRIGHT 2007 ACS on STN

RN 3153-26-2 REGISTRY

ED Entered STN: 16 Nov 1984

CN Vanadium, oxobis(2,4-pentanedionato- κ O₂, κ O₄)-,
 (SP-5-21)- (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Vanadium, oxobis(2,4-pentanedionato)- (6CI, 8CI)

CN Vanadium, oxobis(2,4-pentanedionato- κ O, κ O')-, (SP-5-21)- (9CI)

CN Vanadium, oxobis(2,4-pentanedionato-O,O')-, (SP-5-21)-

OTHER NAMES:

CN Bis(2,4-pentanedionato)oxovanadium

CN Bis(2,4-pentanedionato)oxovanadium(IV)

CN Bis(acetylacetonato)oxovanadium

CN Bis(acetylacetonato)oxovanadium(IV)

CN Bis(acetylacetonato)oxygen vanadium

CN NSC 116105

CN NSC 4659

CN NSC 52327

CN Oxobis(2,4-pentanedionato)vanadium

CN Oxobis(acetylacetonato)vanadium

CN Oxovanadium(II) acetylacetonate

CN Vanadyl bis(2,4-pentanedionate)

CN Vanadyl bis(acetylacetonate)

DR 13930-95-5, 58271-97-9, 21773-11-5, 72007-96-6, 39136-41-9

MF C10 H14 O5 V

CI CCS, COM


LC STN Files: BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX,

CHEMLIST, CSCHEM, DETHERM*, GMELIN*, IFICDB, IFIPAT, IFIUDB, IPA,
MEDLINE, MSDS-OHS, TOXCENTER, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Other Sources: EINECS**, NDSL**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1747 REFERENCES IN FILE CA (1907 TO DATE)

28 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

1748 REFERENCES IN FILE CAPLUS (1907 TO DATE)

23 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L87 ANSWER 11 OF 18 REGISTRY COPYRIGHT 2007 ACS on STN

RN 1763-10-6 REGISTRY

ED Entered STN: 16 Nov 1984

CN Coenzyme A, S-hexadecanoate (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Coenzyme A, palmitate (6CI)

CN Coenzyme A, S-palmitate (7CI, 8CI)

OTHER NAMES:

CN Hexadecanoyl-CoA

CN Hexadecanoyl-coenzyme A

CN Palmitoyl CoA

CN Palmitoyl coenzyme A

CN Palmityl coenzyme A

CN Palmityl-CoA

CN S-Palmityl coenzyme A

CN S-Palmityl-CoA

FS STEREOSEARCH

DR 739357-52-9, 917-46-4, 79251-01-7

MF C37 H66 N7 O17 P3 S

CI COM



LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CHEMCATS, CHEMLIST, CSCHEM, DDFU, DRUGU, EMBASE, MEDLINE, PROMT, TOXCENTER, ULIDAT, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Other Sources: EINECS**

(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1632 REFERENCES IN FILE CA (1907 TO DATE)
 18 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1633 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 11 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L87 ANSWER 12 OF 18 REGISTRY COPYRIGHT 2007 ACS on STN

RN 1190-94-9 REGISTRY

ED Entered STN: 16 Nov 1984

CN L-Lysine, 5-hydroxy-, (5R)- (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN L-Lysine, 5-hydroxy-, erythro-

CN Lysine, 5-hydroxy-, L- (8CI)

OTHER NAMES:

CN (2S,5R)-5-Hydroxylysine

CN (5R)-5-Hydroxy-L-lysine

CN δ-Hydroxy-L-lysine

CN δ-Hydroxylysine

CN 5-Hydroxy-L-lysine

CN 5-Hydroxylysine

CN Hydroxy-L-lysine

CN Hydroxylysine

CN L-δ-Hydroxylysine

CN L-5-Hydroxylysine

CN L-Hydroxylysine

CN Lysine, 5-hydroxy-

FS STEREOSEARCH

DR 13189-95-2, 24722-60-9, 27287-98-5, 28902-93-4, 30528-11-1


MF C6 H14 N2 O3

CI COM

LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CHEMLIST, EMBASE, GMELIN*, IFICDB, IFIUDB,

MEDLINE, NAPRALERT, PIRA, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)


Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

937 REFERENCES IN FILE CA (1907 TO DATE)
59 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
939 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L87 ANSWER 13 OF 18 REGISTRY COPYRIGHT 2007 ACS on STN
RN 513-62-2 REGISTRY
ED Entered STN: 16 Nov 1984
CN Acetic acid, fluoro-, ion(1-) (8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN Fluoroacetate anion
CN Monofluoroacetate anion
MF C2 H2 F O2
CI COM
LC STN Files: ANABSTR, BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT,
CSNB, GMELIN*, TOXCENTER
(*File contains numerically searchable property data)




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

42 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
42 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L87 ANSWER 14 OF 18 REGISTRY COPYRIGHT 2007 ACS on STN
RN 499-83-2 REGISTRY
ED Entered STN: 16 Nov 1984
CN 2,6-Pyridinedicarboxylic acid (CA INDEX NAME)
OTHER NAMES:
CN 2,6-Dicarboxypyridine
CN 2,6-Dipicolinic acid
CN 6-Carboxypicolinic acid


CN Dipicolinic acid
 CN DPA
 CN DPAC
 CN NSC 176
 MF C7 H5 N O4
 CI COM
 LC STN Files: AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS, BIOTECHNO, CA,
 CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM,
 CSNB, DDFU, DRUGU, EMBASE, GMELIN*, IFICDB, IFIPAT, IFIUDB, IPA,
 MEDLINE, MSDS-OHS, PIRA, PROMT, PS, SCISEARCH, SPECINFO, SYNTHLINE,
 TOXCENTER, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: DSL**, EINECS**, TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2028 REFERENCES IN FILE CA (1907 TO DATE)
 227 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 2037 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 7 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L87 ANSWER 15 OF 18 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 357-89-1 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN Pentonic acid, 3-C-carboxy-2,4-dideoxy-2-fluoro- (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Citric acid, fluoro- (6CI, 7CI, 8CI)
 OTHER NAMES:
 CN 1-Fluoro-2-hydroxy-1,2,3-propanetricarboxylic acid
 CN Fluorocitric acid
 CN Monofluorocitric acid
 MF C6 H7 F O7
 CI COM
 LC STN Files: AGRICOLA, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS,
 EMBASE, MEDLINE, TOXCENTER, USPATFULL
 (*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

152 REFERENCES IN FILE CA (1907 TO DATE)
154 REFERENCES IN FILE CAPLUS (1907 TO DATE)
47 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L87 ANSWER 16 OF 18 REGISTRY COPYRIGHT 2007 ACS on STN
RN 328-50-7 REGISTRY

ED Entered STN: 16 Nov 1984

CN Pentanedioic acid, 2-oxo- (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Glutaric acid, 2-oxo- (8CI)

OTHER NAMES:

CN *α*-keto-Glutamic acid

CN *α*-Ketoglutaric acid

CN *α*-Oxoglutaric acid

CN *α*-Oxopentanedioic acid

CN 2-Ketoglutaric acid

CN 2-Oxo-1,5-pentanedioic acid

CN 2-Oxoglutaric acid

CN 2-Oxopentanedioic acid

CN NSC 17391

DR 27175-99-1

MF C5 H6 O5


CI COM

LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM, CSNB, DDFU, DETHERM*, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8731 REFERENCES IN FILE CA (1907 TO DATE)

151 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

8742 REFERENCES IN FILE CAPLUS (1907 TO DATE)

15 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L87 ANSWER 17 OF 18 REGISTRY COPYRIGHT 2007 ACS on STN

RN 144-49-0 REGISTRY

ED Entered STN: 16 Nov 1984

CN Acetic acid, 2-fluoro- (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Acetic acid, fluoro- (8CI, 9CI)


OTHER NAMES:

CN *α*-Fluoroacetic acid

CN Cymanic acid

CN Fluoroacetic acid

CN Fluoroethanoic acid
CN Gifblaar poison
CN HFA
CN Monofluoroacetic acid
DR 9074-77-5
MF C2 H3 F O2
CI COM
LC STN Files: AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, RTECS*, SPECINFO, TOXCENTER, ULIDAT, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1030 REFERENCES IN FILE CA (1907 TO DATE)
37 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1032 REFERENCES IN FILE CAPLUS (1907 TO DATE)
66 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L87 ANSWER 18 OF 18 REGISTRY COPYRIGHT 2007 ACS on STN
RN 103-82-2 REGISTRY
ED Entered STN: 16 Nov 1984
CN Benzeneacetic acid (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Acetic acid, phenyl- (6CI, 8CI)
OTHER NAMES:
CN α -Toluic acid
CN ω -Phenylacetic acid
CN 2-Phenylacetic acid
CN NSC 125718
CN PAA
CN Phenylacetic acid
CN Phenylethanoic acid
MF C8 H8 O2
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DRUGU, EMBASE, GMELIN*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, PIRA, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT, USPAT2, USPATFULL, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

Ph—CH₂—CO₂H

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7400 REFERENCES IN FILE CA (1907 TO DATE)
319 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
7423 REFERENCES IN FILE CAPLUS (1907 TO DATE)
7 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> file registry
FILE 'REGISTRY' ENTERED AT 17:05:29 ON 17 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 MAY 2007 HIGHEST RN 934961-09-8
DICTIONARY FILE UPDATES: 16 MAY 2007 HIGHEST RN 934961-09-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> file zcaplus
FILE 'ZCAPLUS' ENTERED AT 17:05:33 ON 17 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS is strictly prohibited.

FILE COVERS 1907 - 17 May 2007 VOL 146 ISS 21
FILE LAST UPDATED: 16 May 2007 (20070516/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.
'OBI' IS DEFAULT SEARCH FIELD FOR 'ZCAPLUS' FILE

=> d stat que L139
L9 34 SEA FILE=REGISTRY ABB=ON PLU=ON (7532-39-0/BI OR 1763-10-6/BI
OR 103-82-2/BI OR 110-94-1/BI OR 111821-59-1/BI OR 1190-94-9/B
I OR 128-53-0/BI OR 14333-18-7/BI OR 144-49-0/BI OR 157-03-9/BI
OR 21752-32-9/BI OR 27774-13-6/BI OR 3153-26-2/BI OR 328-50-7/
BI OR 34364-34-6/BI OR 35597-44-5/BI OR 357-89-1/BI OR

471-47-6/BI OR 499-83-2/BI OR 56-85-9/BI OR 66-76-2/BI OR
 76-59-5/BI OR 9001-47-2/BI OR 9014-19-1/BI OR 9023-70-5/BI OR
 9029-12-3/BI OR 115-02-6/BI OR 2105-23-9/BI OR 362-66-3/BI OR
 42228-92-2/BI OR 554-77-8/BI OR 56-86-0/BI OR 9031-65-6/BI OR
 9032-20-6/BI)

L11 1 SEA FILE=REGISTRY ABB=ON PLU=ON "A-KETO-GLUTARIC
 ACID"/CN
 L42 151825 SEA FILE=ZCPLUS ABB=ON PLU=ON PAIN?/BI
 L49 1697807 SEA FILE=ZCPLUS ABB=ON PLU=ON (THU OR DMA OR BAC OR PKT OR
 PAC)/RL
 L67 1 SEA FILE=REGISTRY ABB=ON PLU=ON 103-82-2
 L68 1 SEA FILE=REGISTRY ABB=ON PLU=ON 7532-39-0
 L69 1 SEA FILE=REGISTRY ABB=ON PLU=ON 21752-32-9
 L70 1 SEA FILE=REGISTRY ABB=ON PLU=ON 35597-44-5
 L71 1 SEA FILE=REGISTRY ABB=ON PLU=ON 1190-94-9
 L72 1 SEA FILE=REGISTRY ABB=ON PLU=ON 34364-34-6
 L73 1 SEA FILE=REGISTRY ABB=ON PLU=ON 1763-10-6
 L74 1 SEA FILE=REGISTRY ABB=ON PLU=ON 14333-18-7
 L75 1 SEA FILE=REGISTRY ABB=ON PLU=ON 27774-13-6
 L76 3 SEA FILE=REGISTRY ABB=ON PLU=ON L9 AND V>0
 L77 1 SEA FILE=REGISTRY ABB=ON PLU=ON "VANADIUM, OXOBIS(2,4-PENTANE
 DIONATO-KO₂,KO₄)-, (SP-5-21) -"/CN
 L78 1 SEA FILE=REGISTRY ABB=ON PLU=ON 499-83-2
 L79 4 SEA FILE=REGISTRY ABB=ON PLU=ON ("FLUOROACETATE ANION"/CN OR
 "FLUOROACETIC ACID"/CN OR "FLUOROACETATE FREE RADICAL"/CN OR
 "FLUOROACETIC ACID RADICAL CATION"/CN)
 L80 2 SEA FILE=REGISTRY ABB=ON PLU=ON FLUOROCIT?/CN
 L81 1 SEA FILE=REGISTRY ABB=ON PLU=ON 144-49-0
 L82 3 SEA FILE=REGISTRY ABB=ON PLU=ON (L80 OR L81)
 L83 1 SEA FILE=REGISTRY ABB=ON PLU=ON 328-50-7
 L84 1 SEA FILE=REGISTRY ABB=ON PLU=ON L11 OR L83
 L85 1 SEA FILE=REGISTRY ABB=ON PLU=ON 357-89-1
 L86 1 SEA FILE=REGISTRY ABB=ON PLU=ON L85 AND L80
 L87 18 SEA FILE=REGISTRY ABB=ON PLU=ON (L67 OR L68 OR L69 OR L70 OR
 L71 OR L72 OR L73 OR L74 OR L75 OR L76 OR L77 OR L78 OR L79 OR
 L80 OR L81 OR L82 OR L83 OR L84 OR L85 OR L86)
 L88 27497 SEA FILE=ZCPLUS ABB=ON PLU=ON L87
 L89 116 SEA FILE=ZCPLUS ABB=ON PLU=ON L88 AND PAIN?/BI
 L90 55 SEA FILE=ZCPLUS ABB=ON PLU=ON L89 AND PD<20010901
 L91 41 SEA FILE=ZCPLUS ABB=ON PLU=ON L89 AND PRD<20010901
 L92 66 SEA FILE=ZCPLUS ABB=ON PLU=ON (L90 OR L91)
 L93 1393 SEA FILE=ZCPLUS ABB=ON PLU=ON L87 (L) L49
 L94 22 SEA FILE=ZCPLUS ABB=ON PLU=ON L42 AND L93
 L95 11 SEA FILE=ZCPLUS ABB=ON PLU=ON L92 AND L94
 L126 37707 SEA FILE=ZCPLUS ABB=ON PLU=ON ESTROGENS/CT
 L127 11071 SEA FILE=ZCPLUS ABB=ON PLU=ON L126 (L) L49
 L128 51186 SEA FILE=ZCPLUS ABB=ON PLU=ON PAIN/BI
 L129 138 SEA FILE=ZCPLUS ABB=ON PLU=ON L127 AND L128
 L130 38 SEA FILE=ZCPLUS ABB=ON PLU=ON L129 AND PD<20010901
 L131 26 SEA FILE=ZCPLUS ABB=ON PLU=ON L129 AND PRD<20010901
 L132 56 SEA FILE=ZCPLUS ABB=ON PLU=ON (L130 OR L131)
 L136 22188 SEA FILE=ZCPLUS ABB=ON PLU=ON PAIN/CT
 L137 20 SEA FILE=ZCPLUS ABB=ON PLU=ON L132 AND L136
 L139 31 SEA FILE=ZCPLUS ABB=ON PLU=ON L95 OR L137

=> file medline
 FILE 'MEDLINE' ENTERED AT 17:05:55 ON 17 MAY 2007

FILE LAST UPDATED: 16 May 2007 (20070516/UP). FILE COVERS 1950 TO DATE.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> d stat que L122
L9      34 SEA FILE=REGISTRY ABB=ON PLU=ON (7532-39-0/BI OR 1763-10-6/BI
          OR 103-82-2/BI OR 110-94-1/BI OR 111821-59-1/BI OR 1190-94-9/B
          I OR 128-53-0/BI OR 14333-18-7/BI OR 144-49-0/BI OR 157-03-9/BI
          OR 21752-32-9/BI OR 27774-13-6/BI OR 3153-26-2/BI OR 328-50-7/
          BI OR 34364-34-6/BI OR 35597-44-5/BI OR 357-89-1/BI OR
          471-47-6/BI OR 499-83-2/BI OR 56-85-9/BI OR 66-76-2/BI OR
          76-59-5/BI OR 9001-47-2/BI OR 9014-19-1/BI OR 9023-70-5/BI OR
          9029-12-3/BI OR 115-02-6/BI OR 2105-23-9/BI OR 362-66-3/BI OR
          42228-92-2/BI OR 554-77-8/BI OR 56-86-0/BI OR 9031-65-6/BI OR
          9032-20-6/BI)
L11      1 SEA FILE=REGISTRY ABB=ON PLU=ON "A-KETO-GLUTARIC
          ACID"/CN
L67      1 SEA FILE=REGISTRY ABB=ON PLU=ON 103-82-2
L68      1 SEA FILE=REGISTRY ABB=ON PLU=ON 7532-39-0
L69      1 SEA FILE=REGISTRY ABB=ON PLU=ON 21752-32-9
L70      1 SEA FILE=REGISTRY ABB=ON PLU=ON 35597-44-5
L71      1 SEA FILE=REGISTRY ABB=ON PLU=ON 1190-94-9
L72      1 SEA FILE=REGISTRY ABB=ON PLU=ON 34364-34-6
L73      1 SEA FILE=REGISTRY ABB=ON PLU=ON 1763-10-6
L74      1 SEA FILE=REGISTRY ABB=ON PLU=ON 14333-18-7
L75      1 SEA FILE=REGISTRY ABB=ON PLU=ON 27774-13-6
L76      3 SEA FILE=REGISTRY ABB=ON PLU=ON L9 AND V>0
L77      1 SEA FILE=REGISTRY ABB=ON PLU=ON "VANADIUM, OXOBIS(2,4-PENTANE
          DIONATO-KO2,KO4)-, (SP-5-21) - "/CN
L78      1 SEA FILE=REGISTRY ABB=ON PLU=ON 499-83-2
L79      4 SEA FILE=REGISTRY ABB=ON PLU=ON ("FLUOROACETATE ANION"/CN OR
          "FLUOROACETIC ACID"/CN OR "FLUOROACETATE FREE RADICAL"/CN OR
          "FLUOROACETIC ACID RADICAL CATION"/CN)
L80      2 SEA FILE=REGISTRY ABB=ON PLU=ON FLUOROCIT?/CN
L81      1 SEA FILE=REGISTRY ABB=ON PLU=ON 144-49-0
L82      3 SEA FILE=REGISTRY ABB=ON PLU=ON (L80 OR L81)
L83      1 SEA FILE=REGISTRY ABB=ON PLU=ON 328-50-7
L84      1 SEA FILE=REGISTRY ABB=ON PLU=ON L11 OR L83
L85      1 SEA FILE=REGISTRY ABB=ON PLU=ON 357-89-1
L86      1 SEA FILE=REGISTRY ABB=ON PLU=ON L85 AND L80
L87      18 SEA FILE=REGISTRY ABB=ON PLU=ON (L67 OR L68 OR L69 OR L70 OR
          L71 OR L72 OR L73 OR L74 OR L75 OR L76 OR L77 OR L78 OR L79 OR
          L80 OR L81 OR L82 OR L83 OR L84 OR L85 OR L86)
L98      SEL PLU=ON L87 1- NAME : 100 TERMS
L116     11983 SEA FILE=MEDLINE ABB=ON PLU=ON L98
L119     79 SEA FILE=MEDLINE ABB=ON PLU=ON L116 AND PAIN?
L120     54 SEA FILE=MEDLINE ABB=ON PLU=ON L119 AND PD<20010901
L121     81800 SEA FILE=MEDLINE ABB=ON PLU=ON PAIN/CT
L122     21 SEA FILE=MEDLINE ABB=ON PLU=ON L120 AND L121
```

```
=> file medline embase
FILE 'MEDLINE' ENTERED AT 17:06:07 ON 17 MAY 2007
```

```
FILE 'EMBASE' ENTERED AT 17:06:07 ON 17 MAY 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.
```

```
=> d stat que L104
L9      34 SEA FILE=REGISTRY ABB=ON PLU=ON (7532-39-0/BI OR 1763-10-6/BI
          OR 103-82-2/BI OR 110-94-1/BI OR 111821-59-1/BI OR 1190-94-9/B
```

I OR 128-53-0/BI OR 14333-18-7/BI OR 144-49-0/BI OR 157-03-9/BI
 OR 21752-32-9/BI OR 27774-13-6/BI OR 3153-26-2/BI OR 328-50-7/
 BI OR 34364-34-6/BI OR 35597-44-5/BI OR 357-89-1/BI OR
 471-47-6/BI OR 499-83-2/BI OR 56-85-9/BI OR 66-76-2/BI OR
 76-59-5/BI OR 9001-47-2/BI OR 9014-19-1/BI OR 9023-70-5/BI OR
 9029-12-3/BI OR 115-02-6/BI OR 2105-23-9/BI OR 362-66-3/BI OR
 42228-92-2/BI OR 554-77-8/BI OR 56-86-0/BI OR 9031-65-6/BI OR
 9032-20-6/BI)

L11 1 SEA FILE=REGISTRY ABB=ON PLU=ON "A-KETO-GLUTARIC
 ACID"/CN
 L67 1 SEA FILE=REGISTRY ABB=ON PLU=ON 103-82-2
 L68 1 SEA FILE=REGISTRY ABB=ON PLU=ON 7532-39-0
 L69 1 SEA FILE=REGISTRY ABB=ON PLU=ON 21752-32-9
 L70 1 SEA FILE=REGISTRY ABB=ON PLU=ON 35597-44-5
 L71 1 SEA FILE=REGISTRY ABB=ON PLU=ON 1190-94-9
 L72 1 SEA FILE=REGISTRY ABB=ON PLU=ON 34364-34-6
 L73 1 SEA FILE=REGISTRY ABB=ON PLU=ON 1763-10-6
 L74 1 SEA FILE=REGISTRY ABB=ON PLU=ON 14333-18-7
 L75 1 SEA FILE=REGISTRY ABB=ON PLU=ON 27774-13-6
 L76 3 SEA FILE=REGISTRY ABB=ON PLU=ON L9 AND V>0
 L77 1 SEA FILE=REGISTRY ABB=ON PLU=ON "VANADIUM, OXOBIS(2,4-PENTANE
 DIONATO-KO₂,KO4) -, (SP-5-21) -"/CN
 L78 1 SEA FILE=REGISTRY ABB=ON PLU=ON 499-83-2
 L79 4 SEA FILE=REGISTRY ABB=ON PLU=ON ("FLUOROACETATE ANION"/CN OR
 "FLUOROACETIC ACID"/CN OR "FLUOROACETATE FREE RADICAL"/CN OR
 "FLUOROACETIC ACID RADICAL CATION"/CN)
 L80 2 SEA FILE=REGISTRY ABB=ON PLU=ON FLUOROCIT?/CN
 L81 1 SEA FILE=REGISTRY ABB=ON PLU=ON 144-49-0
 L82 3 SEA FILE=REGISTRY ABB=ON PLU=ON (L80 OR L81)
 L83 1 SEA FILE=REGISTRY ABB=ON PLU=ON 328-50-7
 L84 1 SEA FILE=REGISTRY ABB=ON PLU=ON L11 OR L83
 L85 1 SEA FILE=REGISTRY ABB=ON PLU=ON 357-89-1
 L86 1 SEA FILE=REGISTRY ABB=ON PLU=ON L85 AND L80
 L87 18 SEA FILE=REGISTRY ABB=ON PLU=ON (L67 OR L68 OR L69 OR L70 OR
 L71 OR L72 OR L73 OR L74 OR L75 OR L76 OR L77 OR L78 OR L79 OR
 L80 OR L81 OR L82 OR L83 OR L84 OR L85 OR L86)
 L98 SEL PLU=ON L87 1- NAME : 100 TERMS
 L99 37070 SEA L98
 L100 27199 SEA L99 AND PD<20010901
 L101 36 SEA L100 AND PERIPHERAL NERVOUS SYSTEM/BI
 L102 837135 SEA PAIN?
 L103 182 SEA L100 AND L102
 L104 1 SEA L101 AND L103

=> d stat que L108

L9 34 SEA FILE=REGISTRY ABB=ON PLU=ON (7532-39-0/BI OR 1763-10-6/BI
 OR 103-82-2/BI OR 110-94-1/BI OR 111821-59-1/BI OR 1190-94-9/B
 I OR 128-53-0/BI OR 14333-18-7/BI OR 144-49-0/BI OR 157-03-9/BI
 OR 21752-32-9/BI OR 27774-13-6/BI OR 3153-26-2/BI OR 328-50-7/
 BI OR 34364-34-6/BI OR 35597-44-5/BI OR 357-89-1/BI OR
 471-47-6/BI OR 499-83-2/BI OR 56-85-9/BI OR 66-76-2/BI OR
 76-59-5/BI OR 9001-47-2/BI OR 9014-19-1/BI OR 9023-70-5/BI OR
 9029-12-3/BI OR 115-02-6/BI OR 2105-23-9/BI OR 362-66-3/BI OR
 42228-92-2/BI OR 554-77-8/BI OR 56-86-0/BI OR 9031-65-6/BI OR
 9032-20-6/BI)

L11 1 SEA FILE=REGISTRY ABB=ON PLU=ON "A-KETO-GLUTARIC
 ACID"/CN
 L67 1 SEA FILE=REGISTRY ABB=ON PLU=ON 103-82-2

L68 1 SEA FILE=REGISTRY ABB=ON PLU=ON 7532-39-0
 L69 1 SEA FILE=REGISTRY ABB=ON PLU=ON 21752-32-9
 L70 1 SEA FILE=REGISTRY ABB=ON PLU=ON 35597-44-5
 L71 1 SEA FILE=REGISTRY ABB=ON PLU=ON 1190-94-9
 L72 1 SEA FILE=REGISTRY ABB=ON PLU=ON 34364-34-6
 L73 1 SEA FILE=REGISTRY ABB=ON PLU=ON 1763-10-6
 L74 1 SEA FILE=REGISTRY ABB=ON PLU=ON 14333-18-7
 L75 1 SEA FILE=REGISTRY ABB=ON PLU=ON 27774-13-6
 L76 3 SEA FILE=REGISTRY ABB=ON PLU=ON L9 AND V>0
 L77 1 SEA FILE=REGISTRY ABB=ON PLU=ON "VANADIUM, OXOBIS(2,4-PENTANE
 DIONATO-KO₂,KO₄) - , (SP-5-21) - "/CN
 L78 1 SEA FILE=REGISTRY ABB=ON PLU=ON 499-83-2
 L79 4 SEA FILE=REGISTRY ABB=ON PLU=ON ("FLUOROACETATE ANION"/CN OR
 "FLUOROACETIC ACID"/CN OR "FLUOROACETATE FREE RADICAL"/CN OR
 "FLUOROACETIC ACID RADICAL CATION"/CN)
 L80 2 SEA FILE=REGISTRY ABB=ON PLU=ON FLUOROCIT?/CN
 L81 1 SEA FILE=REGISTRY ABB=ON PLU=ON 144-49-0
 L82 3 SEA FILE=REGISTRY ABB=ON PLU=ON (L80 OR L81)
 L83 1 SEA FILE=REGISTRY ABB=ON PLU=ON 328-50-7
 L84 1 SEA FILE=REGISTRY ABB=ON PLU=ON L11 OR L83
 L85 1 SEA FILE=REGISTRY ABB=ON PLU=ON 357-89-1
 L86 1 SEA FILE=REGISTRY ABB=ON PLU=ON L85 AND L80
 L87 18 SEA FILE=REGISTRY ABB=ON PLU=ON (L67 OR L68 OR L69 OR L70 OR
 L71 OR L72 OR L73 OR L74 OR L75 OR L76 OR L77 OR L78 OR L79 OR
 L80 OR L81 OR L82 OR L83 OR L84 OR L85 OR L86)
 L102 837135 SEA PAIN?
 L106 15390 SEA L87
 L107 93 SEA L106 AND L102
 L108 33 SEA L107 AND PD<20010901

=> s L104 or L108
 L142 25 L104 OR L108

=> file embase
 FILE 'EMBASE' ENTERED AT 17:06:33 ON 17 MAY 2007
 Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE COVERS 1974 TO 16 May 2007 (20070516/ED)

EMBASE is now updated daily. SDI frequency remains weekly (default) and biweekly.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d stat que L113
 L9 34 SEA FILE=REGISTRY ABB=ON PLU=ON (7532-39-0/BI OR 1763-10-6/BI
 OR 103-82-2/BI OR 110-94-1/BI OR 111821-59-1/BI OR 1190-94-9/B
 I OR 128-53-0/BI OR 14333-18-7/BI OR 144-49-0/BI OR 157-03-9/BI
 OR 21752-32-9/BI OR 27774-13-6/BI OR 3153-26-2/BI OR 328-50-7/
 BI OR 34364-34-6/BI OR 35597-44-5/BI OR 357-89-1/BI OR
 471-47-6/BI OR 499-83-2/BI OR 56-85-9/BI OR 66-76-2/BI OR
 76-59-5/BI OR 9001-47-2/BI OR 9014-19-1/BI OR 9023-70-5/BI OR
 9029-12-3/BI OR 115-02-6/BI OR 2105-23-9/BI OR 362-66-3/BI OR
 42228-92-2/BI OR 554-77-8/BI OR 56-86-0/BI OR 9031-65-6/BI OR
 9032-20-6/BI)
 L11 1 SEA FILE=REGISTRY ABB=ON PLU=ON "A-KETO-GLUTARIC
 ACID"/CN
 L67 1 SEA FILE=REGISTRY ABB=ON PLU=ON 103-82-2

L68 1 SEA FILE=REGISTRY ABB=ON PLU=ON 7532-39-0
 L69 1 SEA FILE=REGISTRY ABB=ON PLU=ON 21752-32-9
 L70 1 SEA FILE=REGISTRY ABB=ON PLU=ON 35597-44-5
 L71 1 SEA FILE=REGISTRY ABB=ON PLU=ON 1190-94-9
 L72 1 SEA FILE=REGISTRY ABB=ON PLU=ON 34364-34-6
 L73 1 SEA FILE=REGISTRY ABB=ON PLU=ON 1763-10-6
 L74 1 SEA FILE=REGISTRY ABB=ON PLU=ON 14333-18-7
 L75 1 SEA FILE=REGISTRY ABB=ON PLU=ON 27774-13-6
 L76 3 SEA FILE=REGISTRY ABB=ON PLU=ON L9 AND V>0
 L77 1 SEA FILE=REGISTRY ABB=ON PLU=ON "VANADIUM, OXOBIS(2,4-PENTANE
 DIONATO-KO₂,KO₄)-, (SP-5-21)-"/CN
 L78 1 SEA FILE=REGISTRY ABB=ON PLU=ON 499-83-2
 L79 4 SEA FILE=REGISTRY ABB=ON PLU=ON ("FLUOROACETATE ANION"/CN OR
 "FLUOROACETIC ACID"/CN OR "FLUOROACETATE FREE RADICAL"/CN OR
 "FLUOROACETIC ACID RADICAL CATION"/CN)
 L80 2 SEA FILE=REGISTRY ABB=ON PLU=ON FLUOROCIT?/CN
 L81 1 SEA FILE=REGISTRY ABB=ON PLU=ON 144-49-0
 L82 3 SEA FILE=REGISTRY ABB=ON PLU=ON (L80 OR L81)
 L83 1 SEA FILE=REGISTRY ABB=ON PLU=ON 328-50-7
 L84 1 SEA FILE=REGISTRY ABB=ON PLU=ON L11 OR L83
 L85 1 SEA FILE=REGISTRY ABB=ON PLU=ON 357-89-1
 L86 1 SEA FILE=REGISTRY ABB=ON PLU=ON L85 AND L80
 L87 18 SEA FILE=REGISTRY ABB=ON PLU=ON (L67 OR L68 OR L69 OR L70 OR
 L71 OR L72 OR L73 OR L74 OR L75 OR L76 OR L77 OR L78 OR L79 OR
 L80 OR L81 OR L82 OR L83 OR L84 OR L85 OR L86)
 L98 SEL PLU=ON L87 1- NAME : 100 TERMS
 L109 13215 SEA FILE=EMBASE ABB=ON PLU=ON L98
 L110 722 SEA FILE=EMBASE ABB=ON PLU=ON L109 (L) (DT OR AD OR DO OR PK
 OR PD)/CT
 L111 333898 SEA FILE=EMBASE ABB=ON PLU=ON PAIN?
 L112 43 SEA FILE=EMBASE ABB=ON PLU=ON L110 AND L111
 L113 14 SEA FILE=EMBASE ABB=ON PLU=ON L112 AND PD<20010901

=> file stnguide
 FILE 'STNGUIDE' ENTERED AT 17:06:45 ON 17 MAY 2007
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
 AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
 LAST RELOADED: May 11, 2007 (20070511/UP).

=> dup rem L139 L122 L142 L113
 FILE 'ZCAPLUS' ENTERED AT 17:06:59 ON 17 MAY 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 17:06:59 ON 17 MAY 2007

FILE 'EMBASE' ENTERED AT 17:06:59 ON 17 MAY 2007
 Copyright (c) 2007 Elsevier B.V. All rights reserved.
 PROCESSING COMPLETED FOR L139
 PROCESSING COMPLETED FOR L122
 PROCESSING COMPLETED FOR L142
 PROCESSING COMPLETED FOR L113
 L143 73 DUP REM L139 L122 L142 L113 (18 DUPLICATES REMOVED)
 ANSWERS '1-31' FROM FILE ZCAPLUS
 ANSWERS '32-59' FROM FILE MEDLINE

ANSWERS '60-73' FROM FILE EMBASE

=> d ibib abs hitind hitstr L143 1-31; d iall L143 32-59; d iall L143 60-73

L143 ANSWER 1 OF 73 ZCPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 5

ACCESSION NUMBER: 2000:221229 ZCPLUS Full-text

DOCUMENT NUMBER: 133:29514

TITLE: Thermal hyperalgesia and mechanical allodynia produced by intrathecal administration of the human immunodeficiency virus-1 (HIV-1) envelope glycoprotein, gp120

AUTHOR(S): Milligan, E. D.; Mehmert, K. K.; Hinde, J. L.; Harvey, L. O.; Martin, D.; Tracey, K. J.; Maier, S. F.; Watkins, L. R.

CORPORATE SOURCE: Department of Psychology, University of Colorado at Boulder, Boulder, CO, USA

SOURCE: Brain Research (2000), 861(1), 105-116

CODEN: BRREAP; ISSN: 0006-8993

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Astrocytes and microglia in the spinal cord have recently been reported to contribute to the development of peripheral inflammation-induced exaggerated pain states. Both lowering of thermal pain threshold (thermal hyperalgesia) and lowering of response threshold to light tactile stimuli (mech. allodynia) have been reported. The notion that spinal cord glia are potential mediators of such effects is based on the disruption of these exaggerated pain states by drugs thought to preferentially affect glial function. Activation of astrocytes and microglia can release many of the same substances that are known to mediate thermal hyperalgesia and mech. allodynia. The aim of the present series of studies was to determine whether exaggerated pain states could also be created in rats by direct, intraspinal immune activation of astrocytes and microglia. The immune stimulus used was peri-spinal (intrathecal, i.t.) application of the Human Immunodeficiency Virus type 1 (HIV-1) envelope glycoprotein, gp120. This portion of HIV-1 is known to bind to and activate microglia and astrocytes. Robust thermal hyperalgesia (tail-flick, TF, and Hargreaves tests) and mech. allodynia (von Frey and touch-evoked agitation tests) were observed in response to i.t. gp120. Heat denaturing of the complex protein structure of gp120 blocked gp120-induced thermal hyperalgesia. Lastly, both thermal hyperalgesia and mech. allodynia to i.t. gp120 were blocked by spinal pretreatment with drugs (fluorocitrate and CNI-1493) thought to preferentially disrupt glial function.

CC 15-8 (Immunochemistry)

Section cross-reference(s): 1

IT Pain

Pain

Skin, disease

Skin, disease

(allodynia; thermal hyperalgesia and mech. allodynia produced by intrathecal administration of HIV-1 virus glycoprotein gp120)

IT Pain

(hyperalgesia, thermal; thermal hyperalgesia and mech. allodynia produced by intrathecal administration of HIV-1 virus glycoprotein gp120)

IT 357-89-1 164301-51-3, Cni-1493


RL: **BAC** (*Biological activity or effector, except adverse*); BSU

(*Biological study, unclassified*); THU (*Therapeutic use*); BIOL

(*Biological study*); USES (*Uses*)

(thermal hyperalgesia and mech. allodynia produced by intrathecal administration of HIV-1 virus glycoprotein gp120 blocking by)

IT 357-89-1
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (thermal hyperalgesia and mech. allodynia produced by intrathecal
 administration of HIV-1 virus glycoprotein gp120 blocking by)
 RN 357-89-1 ZCPLUS
 CN Pentacic acid, 3-C-carboxy-2,4-dideoxy-2-fluoro- (CA INDEX NAME)



REFERENCE COUNT: 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L143 ANSWER 2 OF 73 ZCPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 7
 ACCESSION NUMBER: 1997:645658 ZCPLUS Full-text
 DOCUMENT NUMBER: 127:305698
 TITLE: Manipulations of zinc in the spinal cord, by intrathecal injection of zinc chloride, disodium-calcium-EDTA, or dipicolinic acid, alter nociceptive activity in mice
 AUTHOR(S): Larson, Alice A.; Kitto, Kelley F.
 CORPORATE SOURCE: Department of Veterinary Pathobiology, University of Minnesota, St. Paul, MN, USA
 SOURCE: Journal of Pharmacology and Experimental Therapeutics (1997), 282(3), 1319-1325
 CODEN: JPETAB; ISSN: 0022-3565
 PUBLISHER: Williams & Wilkins
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Zinc is concentrated in the dorsal horn of the spinal cord and has been proposed to alter excitability of primary afferent C-fibers, structures believed to be important in nociceptive transmission. Based on the inhibitory effect of zinc on the activity of various other neurotransmitters that play a role in nociception, we tested the hypothesis that zinc modulates pain transmission. To test this, we examined the effect of exogenous zinc, administered intrathecally (i.t.), on nociception in the mouse. We also assessed the impact of decreased concns. of endogenously occurring zinc in the extracellular fluid brought about by an i.t. injection of either EDTA disodium-calcium salt (Ca++EDTA), a calcium-saturated, membrane-impermeable chelator of divalent cations, or of dipicolinic acid, a zinc chelator. Injection of zinc produced a dose-related antinociceptive effect, optimal at 90 min in the writhing assay, but had no effect on tail-flick response latencies. In contrast, injection of either Ca++EDTA or dipicolinic acid produced a dose-related hyperalgesia in the tail-flick assay at 90 min after injection. Responses induced in the writhing assay were unaffected by Ca++EDTA. Although zinc had no effect on thermal nociception, the hyperalgesic effect of Ca++EDTA was antagonized by coadministration of Ca++EDTA with zinc. Similarly, the antinociceptive effect of zinc on writhing responses was attenuated when coadministered with Ca++EDTA. Zinc also inhibited primary afferent C-fiber activity because 10 ng of zinc i.t. inhibited the behavioral response induced by injection i.t. of 1 nmol of capsaicin. Neither zinc nor Ca++EDTA altered writhing or tail-flick

latencies, resp., when injected intracerebroventricularly. These findings support the hypothesis that endogenous zinc, localized in the dorsal horn of the spinal cord, plays a role in the regulation of pain.

CC 13-1 (Mammalian Biochemistry)

IT Pain


Spinal cord
 (manipulations of zinc in spinal cord by intrathecal injection of zinc chloride and disodium-calcium-EDTA or dipicolinic acid in relation to nociceptive activity)

IT 60-00-4, EDTA, biological studies 499-83-2, Dipicolinic acid
 RL: *BAC (Biological activity or effector, except adverse); BSU*
(Biological study, unclassified); BIOL (Biological study)
 (manipulations of zinc in spinal cord by intrathecal injection of zinc chloride and disodium-calcium-EDTA or dipicolinic acid in relation to nociceptive activity)

IT 499-83-2, Dipicolinic acid
 RL: *BAC (Biological activity or effector, except adverse); BSU*
(Biological study, unclassified); BIOL (Biological study)
 (manipulations of zinc in spinal cord by intrathecal injection of zinc chloride and disodium-calcium-EDTA or dipicolinic acid in relation to nociceptive activity)

RN 499-83-2 ZCPLUS

CN 2,6-Pyridinedicarboxylic acid (CA INDEX NAME)



REFERENCE COUNT: 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L143 ANSWER 3 OF 73 ZCPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:15122 ZCPLUS Full-text
 DOCUMENT NUMBER: 144:114572
 TITLE: Disc shunt for treating back pain
 PATENT ASSIGNEE(S): Yeung, Jeffrey E., USA
 SOURCE: PCT Int. Appl., 68 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006002417	A2	20060105	WO 2005-US22749	20050622
WO 2006002417	A3	20060316		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF,			

CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM,
 KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG,
 KZ, MD, RU, TJ, TM
 WO 2002064044 A2 20020822 WO 2002-US204301 20020213 <--
 WO 2002064044 A3 20040108
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
 YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
 GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
 GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2002240360 A1 20020828 AU 2002-240360 20020213 <--
 EP 1399077 A2 20040324 EP 2002-706259 20020213 <--
 EP 1399077 B1 20060823
 R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC,
 NL, PT, SE, TR
 AT 336953 T 20060915 AT 2002-706259 20020213 <--
 US 2004210209 A1 20041021 US 2004-840816 20040507 <--
 AU 2004238302 A1 20041125 AU 2004-238302 20040507
 WO 2004101015 A2 20041125 WO 2004-US14368 20040507
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG
 EP 1620024 A2 20060201 EP 2004-760924 20040507
 EP 1620024 B1 20070404
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR
 BR 2004010425 A 20060613 BR 2004-10425 20040507
 JP 2007501676 T 20070201 JP 2006-529365 20040507
 CA 2560222 A1 20060105 CA 2005-2560222 20050622
 US 2006247600 A1 20061102 US 2005-555895 20051107
 IN 2005CN03034 A 20070302 IN 2005-CN3034 20051116
 PRIORITY APPLN. INFO.: US 2003-470181 A 20030721
 US 2004-582228P P 20040622
 US 2004-587837P P 20040714
 US 2005-660120P P 20050308
 US 2001-268666P P 20010213 <--
 US 2001-297556P P 20010611 <--
 US 2001-310131P P 20010803 <--
 US 2001-325111P P 20010926
 US 2001-330260P P 20011017
 WO 2002-US4301 W 20020213
 US 2003-468770P P 20030507
 US 2003-480057P P 20030620
 US 2003-503553P P 20030916
 US 2003-529065P P 20031212
 WO 2004-US14368 W 20040507
 WO 2005-US22749 W 20050622

AB The intervertebral disk is avascular. With aging, nutrients and oxygen transporting through the endplates diminish. The disk degenerates, and **pain** ensues. Conduits are delivered through a pedicle or vertebral body into the intervertebral disk to re-establish the exchange of nutrients and waste between the disk and bodily circulation to slow, stop or reverse disk degeneration and relieve **pain**. Endplate plugs may be deployed to seal gaps between the conduits and the endplates to prevent immune responses to the nucleus pulposus and to preserve the hydrostatic pressure within the disk.

IC ICM A61B017-70
ICS A61B017-88; A61F002-44

CC 63-7 (Pharmaceuticals)
Section cross-reference(s): 1, 2, 15

ST spine **pain** vertebral disk shunt app

IT Thrombospondins
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(1; disk shunt for treating back **pain**)

IT Collagens, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(XVIII fragment; disk shunt for treating back **pain**)

IT Calreticulin
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino-terminal fragment (vasostatin); disk shunt for treating back **pain**)

IT Antibodies and Immunoglobulins
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-VEGF; disk shunt for treating back **pain**)

IT Medical goods
(conduits; disk shunt for treating back **pain**)

IT Angiogenesis
Biocompatibility
Circulation
Coating materials
Immunomodulators
Immunosuppressants
Needles (tools)
Nutrients
Pain
Pore size distribution
(disk shunt for treating back **pain**)

IT Collagens, biological studies
Corticosteroids, biological studies
Fibronectins
Interleukin 12
Neoprene rubber, biological studies
Polyoxyalkylenes, biological studies
Polysiloxanes, biological studies
Polyurethanes, biological studies
Prostaglandins
Serpentine-group minerals
Sialic acids
Steroids, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(disk shunt for treating back **pain**)

IT Medical goods
(drills; disk shunt for treating back **pain**)

IT Polysiloxanes, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fluoro; disk shunt for treating back pain)

IT Spinal column
(intervertebral disk; disk shunt for treating back pain)

IT Medical goods
(plungers; disk shunt for treating back pain)

IT Medical goods
(sheaths; disk shunt for treating back pain)

IT Glycosaminoglycans, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sulfated; disk shunt for treating back pain)

IT Interferons
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α ; disk shunt for treating back pain)

IT Transforming growth factors
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(β -; disk shunt for treating back pain)

IT 127464-60-2, Vegf
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antibodies; disk shunt for treating back pain)

IT 50-18-0, Cyclophosphamide 50-24-8, Prednisolone 50-35-1, Thalidomide 50-44-2, 6-Mercaptopurine 50-99-7, Glucose, biological studies 51-35-4, Hydroxyproline 53-03-2, Prednisone 54-62-6, Aminopterin 56-45-1, Serine, biological studies 59-05-2, Methotrexate 59-23-4, Galactose, biological studies 60-54-8, Tetracycline 61-57-4, Niridazole 72-19-5, Threonine, biological studies 83-43-2, Methylprednisolone 107-25-5, Vinyl methyl ether 126-99-8, Chloroprene 305-03-3, Chlorambucil 306-53-6, Pentammin 362-07-2, Panzem 446-86-6, Azathioprine 671-16-9, Procarbazine 745-65-3, Prostaglandin e1 1190-94-9, Hydroxyllysine 1309-48-4, Magnesium oxide, biological studies 1343-88-0, Trisomin 1398-61-4, Chitin 3416-24-8, Glucosamine 4759-48-2, Isotretinoin 6556-12-3, Glucuronic acid 6834-92-0, Sodium metasilicate 7535-00-4, Galactosamine 9000-94-6, Antithrombin iii 9002-61-3, Human chorionic gonadotropin 9002-89-5, Polyvinyl alcohol 9003-01-4, Polyacrylic acid 9003-05-8, Polyacrylamide 9003-39-8, Polyvinylpyrrolidone 9004-35-7 9004-61-9, Hyaluronan 9012-09-3 9012-76-4, Chitosan 9016-00-6, Polydimethylsiloxane 9025-39-2, Heparinase 9032-43-3, Cellulose sulfate 10043-35-3, Boric acid, biological studies 10193-36-9, Orthosilicic acid 10540-29-1, Tamoxifen 14475-38-8, Silanol 14987-04-3, Magnosil 15866-90-7, Col3 24968-12-5, Polybutylene terephthalate 25014-41-9, Polyacrylonitrile 25087-26-7, Polymethacrylic acid 25249-16-5 25322-68-3, Polyethylene glycol 25322-68-3D, Polyethylene glycol, cross-linkage products 25322-69-4, Polypropylene oxide 26022-14-0, Polyhydroxyethylacrylate 26062-94-2, Polybutylene terephthalate 27302-90-5, Oxisuran 31900-57-9, Polydimethylsiloxane 33069-62-4, Taxol 38101-59-6, Im862 50885-97-7, Polyhydroxymethylmethacrylate 59865-13-3, Cyclosporin A 86090-08-6, Angiostatin 99519-84-3, Carboxyamidotriazole 117048-59-6, Combretastatin a4 126509-46-4, Eponemycin 129298-91-5, Tnp470 134381-21-8, Epoxomicin 148717-90-2, Squalamine 154039-60-8, Marimastat 169590-42-5, Celebrex 169799-04-6, CGS27023A 179324-69-7, Velcade 179545-77-8, Bay 12-9566 180288-69-1, Herceptin 184475-35-2, Iressa 187888-07-9, Endostatin 188968-51-6, Emd121974 192329-42-3, AG3340 204005-46-9, Su5416 205923-56-4, Erbitux 212142-18-2, Ptk787 216974-75-3, Avastin 220137-31-5 252916-29-3, Su6668 259188-38-0,

BMS275291 305838-77-1, Neovastat 528900-03-0, Anginex
 RL: DEV (Device component use); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (disk shunt for treating back pain)


IT 9010-98-4
 RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (neoprene rubber; disk shunt for treating back pain)

IT 1190-94-9, Hydroxylysine
 RL: DEV (Device component use); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (disk shunt for treating back pain)

RN 1190-94-9 ZCPLUS

CN L-Lysine, 5-hydroxy-, (5R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L143 ANSWER 4 OF 73 ZCPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:1004367 ZCPLUS Full-text
 DOCUMENT NUMBER: 143:292564
 TITLE: Formulations containing jojoba alcohol useful for the treatment of varicella zoster virus infections
 INVENTOR(S): Verbiscar, Anthony J.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 14 pp., Cont.-in-part of U.S. Ser. No. 795,589.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005203187	A1	20050915	US 2005-64435	20050222 <--
US 2001053800	A1	20011220	US 2001-788763	20010221 <--
US 6703052	B2	20040309		
US 2001012840	A1	20010809	US 2001-795589	20010228 <--
US 6858232	B2	20050222		
WO 2006112938	A1	20061026	WO 2006-US5714	20060217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				

KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

US 1998-87406P	P 19980601 <--
US 1999-320700	B2 19990526 <--
WO 1999-US11900	A 19990527 <--
US 2001-795589	A2 20010228 <--
US 2005-64435	A 20050222

OTHER SOURCE(S): MARPAT 143:292564

AB Jojoba alc., a mixture of long chain monounsatd. alcs., is an oily liquid at moderate ambient temps. It is readily absorbed by human skin where it relieves irritation and inhibits the formation of lesions caused by viruses. The inhibitory action is applicable to enveloped viruses which express as sores at dermal surfaces in humans. When applied topically to an incipient herpes episode, it will quickly penetrate the epidermis to the subdermal vascular cells and suppress viral replication which leads to inflammation and the formation of blisters on the face, genital and other skin and mucosal areas. Fumaric acid and malonic acid at low concns. also inhibit the replication of varicella zoster virus in human cell cultures, with no cellular toxicity. Compns. of certain low mol. weight organic acids in jojoba alc. enhance antiviral activity. Topical treatment of shingles with a low concentration of fumaric acid in jojoba alc. terminates the episode. This combination drug acts by a dual mechanism wherein the jojoba alc. blocks viral fusion by a lipoidal mode, and the polycarboxylic acids inhibit viral fusion by an ionic mode. The combination drug can also be effective in treating chicken pox. Jojoba alc. is a carrier and transdermal delivery system for these and other pharmacol. active agents for the relief of **pain** and treatment of other conditions which occur at or under the surface of the skin. Topically applied jojoba alc. is non-toxic and safe for animals and humans. For example, 40 mg of malic acid was dissolved in 3 mL of alc. and 3 mL of jojoba alc. resulting in a lotion containing 0.8% malic acid. The lotion applied to human skin absorbed readily and was nonirritating, leaving no residue. Also, a male patient who had chicken pox as a child and experienced a recurrence as shingles was treated topically with a Viracol A Plus formulation containing 90% Viracol (jojoba alc. + 0.5% α -tocopherol), 10% ethanol and 0.2% fumaric acid in combination with oral acyclovir at 400 mg 2+/day. After 8 days of Viracol A Plus treatment the blisters on his arm had disappeared completely, and his waist was healing with a few small residual sores and some inflammation. This did not occur with acyclovir alone. Some neuralgia in his arm remained but the **pain** in his waist subsided substantially. The subject continued on his 3 remaining tablets of acyclovir at 1/day, and continued to use Viracol A Plus on his waist until it too healed completely within 2 wk.

IC ICM A61K031-19

ICS A61K009-00

INCL 514574000; 424400000

CC 63-6 (Pharmaceuticals)


Section cross-reference(s): 1

IT 50-21-5, Lactic acid, biological studies 50-78-2, Acetylsalicylic acid 65-85-0, Benzoic acid, biological studies 69-72-7, Salicylic acid, biological studies 77-92-9, Citric acid, biological studies 79-14-1, Glycolic acid, biological studies 87-69-4, L-Tartaric acid, biological studies 97-67-6, L-Malic acid 110-15-6, Succinic acid, biological studies 110-16-7, Maleic acid, biological studies 110-17-8, Fumaric acid, biological studies 110-94-1, Glutaric acid 127-17-3, Pyruvic acid, biological studies 133-37-9, DL-Tartaric acid 141-82-2, Malonic acid, biological studies 320-77-4, Isocitric acid 328-42-7, Oxalacetic acid 328-50-7, 2-Oxoglutaric acid 6915-15-7 353288-96-7, Viracol Plus

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(topical compns. containing jojoba alc. and carboxylic acids for treatment

of varicella zoster virus infections)
 IT 328-50-7, 2-Oxoglutaric acid
 RL: *PAC* (*Pharmacological activity*); *THU* (*Therapeutic use*); *BIOL* (*Biological study*); *USES* (*Uses*)
 (topical compns. containing jojoba alc. and carboxylic acids for treatment of varicella zoster virus infections)
 RN 328-50-7 ZCPLUS
 CN Pentanedioic acid, 2-oxo- (CA INDEX NAME)



L143 ANSWER 5 OF 73 ZCPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:985327 ZCPLUS Full-text
 DOCUMENT NUMBER: 143:260368
 TITLE: Method and composition using pyruvates and
 α-keto acids for treating mammalian diseases and
 injuries caused by the overexpression of peroxynitrite
 INVENTOR(S): Martin, Alain
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 24 pp., Cont.-in-part of U.S.
 Ser. No. 747,963.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005197397	A1	20050908	US 2005-56759	20050211
US 2003105162	A1	20030605	US 2002-205354	20020725 <--
US 2004220265	A1	20041104	US 2003-747963	20031230
WO 2006086643	A1	20060817	WO 2006-US4753	20060210
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:			US 2002-205354	A2 20020725
			US 2003-747963	A2 20031230
			US 2001-313871P	P 20010821 <--
			US 2002-205353	A2 20020725
			WO 2002-US26060	A 20020815
			US 2005-56759	A 20050211

AB The invention provides a method for treating wounds and diseases in mammals, caused by mammalian cells involved in an inflammatory response, by altering indigenous in vivo levels of peroxynitrous acid, and salts thereof. The

method comprises contacting the mammalian cells with a therapeutically effective amount of a reactive oxygen species mediator, wherein the reactive oxygen species mediator is selected from the group consisting of pyruvates, pyruvate precursors, α -keto acids having four or more carbon atoms, precursors of α -keto acids having four or more carbon atoms, and the salts thereof, wherein mediation of reactive oxygen species results in mediation of peroxy nitrous acid. The invention further provides a pharmaceutical composition for treating wounds and diseases in mammals, caused by mammalian cells involved in an inflammatory response, by altering indigenous in vivo levels of peroxy nitrous acid, and salts thereof.

IC ICM A61K031-19

INCL 514557000

CC 1-7 (Pharmacology)

Section cross-reference(s) : 63

IT AIDS (disease)

Alzheimer's disease

Analgesics

Angiogenesis

Angiogenesis inhibitors

Anti-AIDS agents

Anti-Alzheimer's agents

Anti-inflammatory agents

Anti-ischemic agents

Antiarthritics

Antibacterial agents

Antidiabetic agents

Antihistamines

Antioxidants

Antiparkinsonian agents

Antirheumatic agents

Antitumor agents

Antiulcer agents

Antiviral agents

Arthritis

Atherosclerosis

Cardiovascular agents

Cardiovascular system, disease

Combination chemotherapy

Diabetes mellitus

Digestive tract, disease

Drug delivery systems

Erythema

Fungicides

Gastrointestinal agents

Human

Human immunodeficiency virus

Inflammation

Ischemia

Leukocyte

Multiple sclerosis

Neoplasm

Nervous system, disease

Nervous system agents

Pain

Parkinson's disease

Psoriasis

Rheumatoid arthritis

Skin, disease

Sunburn

Swelling, biological

Transplant and Transplantation

Wound

Wound healing promoters

(pyruvates and α -keto acids for treating mammalian diseases and injuries caused by overexpression of peroxynitrite)

IT 56-40-6D, Glycine, α -keto acid conjugates 56-41-7D, L-Alanine, α -keto acid conjugates 61-90-5D, L-Leucine, α -keto acid conjugates 63-91-2D, L-Phenylalanine, α -keto acid conjugates 72-18-4D, L-Valine, α -keto acid conjugates 73-32-5D, L-Isoleucine, α -keto acid conjugates 113-24-6, Sodium pyruvate 127-17-3, Pyruvic acid, biological studies 127-17-3D, aluminum complexes 127-17-3D, Pyruvic acid, derivs. and salts 328-42-7, Oxaloacetic acid 328-50-7, α -keto-Glutamic acid 600-18-0 631-66-3, Pyruvamide 759-05-7, α -keto-Isovaleric acid 923-32-0D, Cystine, -keto acid conjugates 2392-63-4 2492-75-3 2922-61-4, Lithium pyruvate 3184-35-8 3997-91-9 4151-33-1, Potassium pyruvate 16947-06-1 17686-94-1, Ammonium pyruvate 18983-79-4, Magnesium pyruvate 24887-16-9, Zinc pyruvate 52009-14-0, Calcium pyruvate 68259-69-8 90088-56-5 145482-34-4, Manganese pyruvate 152102-61-9 863879-42-9

RL: *PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)*

(pyruvates and α -keto acids for treating mammalian diseases and injuries caused by overexpression of peroxynitrite)


IT 328-50-7, α -keto-Glutamic acid

RL: *PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)*

(pyruvates and α -keto acids for treating mammalian diseases and injuries caused by overexpression of peroxynitrite)

RN 328-50-7 ZCPLUS

CN Pentanedioic acid, 2-oxo- (CA INDEX NAME)



L143 ANSWER 6 OF 73 ZCPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:173370 ZCPLUS Full-text

DOCUMENT NUMBER: 138:210328

TITLE: Anti-inflammatory oxytocin formulations

INVENTOR(S): Uvnaes-Moberg, Kerstin; Lundeberg, Thomas

PATENT ASSIGNEE(S): Swed.

SOURCE: PCT Int. Appl., 65 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003017922	A2	20030306	WO 2002-SE1560	20020902 <--
WO 2003017922	A3	20031009		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
 CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2002328000 A1 20030310 AU 2002-328000 20020902 <--
 EP 1432434 A2 20040630 EP 2002-763166 20020902 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
 US 2006234919 A1 20061019 US 2004-488166 20040301 <--
 PRIORITY APPLN. INFO.: SE 2001-2910 A 20010831 <--
 WO 2002-SE1560 W 20020902

OTHER SOURCE(S): MARPAT 138:210328

AB The present invention relates to the use of substances with oxytocin for the preparation of pharmaceutical composition against inflammation. It also relates to a pharmaceutical composition comprising at least one substance with oxytocin activity against inflammation.

IC ICM A61K

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 2

IT *Estrogens*

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(anti-inflammatory oxytocin formulations)

IT *Pain*

(hyperalgesia; anti-inflammatory oxytocin formulations)

L143 ANSWER 7 OF 73 ZCPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:154262 ZCPLUS Full-text

DOCUMENT NUMBER: 138:198610

TITLE: Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate

INVENTOR(S): Pulaski, Steven P.; Kundel, Susan

PATENT ASSIGNEE(S): Pharmacia Corporation, USA

SOURCE: PCT Int. Appl., 148 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003015799	A1	20030227	WO 2002-US25673	20020813 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

US 2003114416	A1	20030619	US 2002-215539	20020809 <--
CA 2457452	A1	20030227	CA 2002-2457452	20020813 <--
AU 2002336344	A1	20030303	AU 2002-336344	20020813 <--
AU 2002336344	A2	20030303		
EP 1416941	A1	20040512	EP 2002-773188	20020813 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002011977	A	20040921	BR 2002-11977	20020813 <--
JP 2005501850	T	20050120	JP 2003-520758	20020813 <--
CN 1575182	A	20050202	CN 2002-820121	20020813 <--
ZA 2004001163	A	20050622	ZA 2004-1163	20040212 <--
PRIORITY APPLN. INFO.:				
US 2001-312211P P 20010814 <--				
US 2002-215539 A 20020809				
WO 2002-US25673 W 20020813				

OTHER SOURCE(S) : MARPAT 138:198610

AB A method of treating, preventing, or inhibiting **pain**, inflammation, or inflammation-associated disorder in a subject in need of such treatment or prevention includes treating the subject with chondroitin sulfate and a cyclooxygenase-2 selective inhibitor, or a prodrug thereof, wherein the amount of chondroitin sulfate and the amount of a cyclooxygenase-2 selective inhibitor or a pharmaceutically acceptable salt or prodrug thereof together constitute a **pain**- or inflammation-suppressing treatment or prevention effective amount Glucosamine can optionally be present. Compns. that contain the combination of chondroitin sulfate and cyclooxygenase-2 selective inhibitor and, optionally, the glucosamine, are disclosed, as are pharmaceutical compns.

IC ICM A61K031-737
 ICS A61K031-42; A61K031-501; A61K031-415; A61P029-00; A61K031-737;
 A61K031-42; A61K031-737; A61K031-50; A61K031-737; A61K031-501;
 A61K031-737; A61K031-415

CC 1-7 (Pharmacology)
 Section cross-reference(s) : 63

ST chondroitin sulfate cyclooxygenase 2 inhibitor analgesic antiinflammatory;
pain inflammation chondroitin sulfate COX2 inhibitor glucosamine

IT Inflammation
 (Crohn's disease; cyclooxygenase 2 inhibitor and chondroitin sulfate for treatment and prevention of **pain** and inflammation)

IT Intestine, disease
 (Crohn's; cyclooxygenase 2 inhibitor and chondroitin sulfate for treatment and prevention of **pain** and inflammation)

IT Swelling, biological
 (after injury; cyclooxygenase 2 inhibitor and chondroitin sulfate for treatment and prevention of **pain** and inflammation)

IT Anemia (disease)
 (aplastic; cyclooxygenase 2 inhibitor and chondroitin sulfate for treatment and prevention of **pain** and inflammation)

IT Bronchi, disease
 Inflammation
 (bronchitis; cyclooxygenase 2 inhibitor and chondroitin sulfate for treatment and prevention of **pain** and inflammation)

IT Joint, anatomical
 (bursa, bursitis; cyclooxygenase 2 inhibitor and chondroitin sulfate for treatment and prevention of **pain** and inflammation)

IT Mycosis
 (candidiasis; cyclooxygenase 2 inhibitor and chondroitin sulfate for treatment and prevention of **pain** and inflammation)

IT Ischemia
 (cardiac; cyclooxygenase 2 inhibitor and chondroitin sulfate for treatment and prevention of **pain** and inflammation)

IT Intestine, neoplasm

(colorectal; cyclooxygenase 2 inhibitor and chondroitin sulfate for treatment and prevention of **pain** and inflammation)

IT Eye, disease
Inflammation
(conjunctivitis; cyclooxygenase 2 inhibitor and chondroitin sulfate for treatment and prevention of **pain** and inflammation)

IT Menstrual disorder
(cramps; cyclooxygenase 2 inhibitor and chondroitin sulfate for treatment and prevention of **pain** and inflammation)

IT AIDS (disease)
Alzheimer's disease
Analgesics
Anti-AIDS agents
Anti-Alzheimer's agents
Anti-inflammatory agents
Anti-ischemic agents
Antiarthritics
Antiasthmatics
Antidiabetic agents
Antipyretics
Antirheumatic agents
Antitumor agents
Antiulcer agents
Arthritis
Asthma
Behcet's syndrome
Blood vessel, disease
Burn
Calculi, renal
Cardiovascular agents
Connective tissue, disease
Dermatitis
Digestive tract, disease
Drug delivery systems
Eczema
Eye, disease
Fever and Hyperthermia
Gastrointestinal agents
Gout
Headache
Hodgkin's disease
Human
Human herpesvirus
Human immunodeficiency virus
Inflammation
Multiple sclerosis
Myasthenia gravis
Neoplasm
Nervous system, disease
Nervous system agents
Osteoarthritis
Pain
Psoriasis
Rheumatic fever
Rheumatoid arthritis
Sarcoidosis
Skin, disease
Wound
Wound healing promoters
(cyclooxygenase 2 inhibitor and chondroitin sulfate for treatment and

prevention of **pain** and inflammation)

IT Mental and behavioral disorders
(dementia, cortical; cyclooxygenase 2 inhibitor and chondroitin sulfate for treatment and prevention of **pain** and inflammation)

IT Dentistry
(dental **pain**; cyclooxygenase 2 inhibitor and chondroitin sulfate for treatment and prevention of **pain** and inflammation)

IT Tendon
(disease, tendinitis; cyclooxygenase 2 inhibitor and chondroitin sulfate for treatment and prevention of **pain** and inflammation)

IT Lung, disease
(edema; cyclooxygenase 2 inhibitor and chondroitin sulfate for treatment and prevention of **pain** and inflammation)

IT Drug delivery systems
(enteric; cyclooxygenase 2 inhibitor and chondroitin sulfate for treatment and prevention of **pain** and inflammation)

IT Stomach, disease
(gastric varices; cyclooxygenase 2 inhibitor and chondroitin sulfate for treatment and prevention of **pain** and inflammation)

IT Ulcer
(gastric; cyclooxygenase 2 inhibitor and chondroitin sulfate for treatment and prevention of **pain** and inflammation)

IT Inflammation
Stomach, disease
(gastritis; cyclooxygenase 2 inhibitor and chondroitin sulfate for treatment and prevention of **pain** and inflammation)

IT Gingiva; disease
Inflammation
(gingivitis; cyclooxygenase 2 inhibitor and chondroitin sulfate for treatment and prevention of **pain** and inflammation)

IT Antiviral agents
(herpes simplex infection; cyclooxygenase 2 inhibitor and chondroitin sulfate for treatment and prevention of **pain** and inflammation)

IT Allergy
(hypersensitivity; cyclooxygenase 2 inhibitor and chondroitin sulfate for treatment and prevention of **pain** and inflammation)

IT Intestine, disease
(inflammatory; cyclooxygenase 2 inhibitor and chondroitin sulfate for treatment and prevention of **pain** and inflammation)

IT Connective tissue
Eye, disease
(injury; cyclooxygenase 2 inhibitor and chondroitin sulfate for treatment and prevention of **pain** and inflammation)

IT Autoimmune disease
(insulin-dependent diabetes mellitus; cyclooxygenase 2 inhibitor and chondroitin sulfate for treatment and prevention of **pain** and inflammation)

IT Diabetes mellitus
(insulin-dependent; cyclooxygenase 2 inhibitor and chondroitin sulfate for treatment and prevention of **pain** and inflammation)

IT Intestine, disease
(irritable bowel syndrome; cyclooxygenase 2 inhibitor and chondroitin sulfate for treatment and prevention of **pain** and inflammation)

IT Heart, disease
(ischemia; cyclooxygenase 2 inhibitor and chondroitin sulfate for treatment and prevention of **pain** and inflammation)